Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial.

publication — a durable, citable reference into the African DSI DataBank's federated catalog.

Last updated 8/28/2026, 10:24:43 PM

Cite this record

African DSI DataBank. Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial.. AFDSI-PUB-890. 2026. https://hub.africandsidatabank.africa/cite/AFDSI-PUB-890 Mirrored from data source: PubMed: https://pubmed.ncbi.nlm.nih.gov/42660235/.Copy citation

@misc{AFDSIPUB890,
  title        = {Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial.},
  author       = {{African DSI DataBank}},
  year         = {2026},
  howpublished = {\url{https://hub.africandsidatabank.africa/cite/AFDSI-PUB-890}},
  note         = {African DSI DataBank citable identifier AFDSI-PUB-890; Mirrored from data source: PubMed: https://pubmed.ncbi.nlm.nih.gov/42660235/}
}

AFDSI-PUB-890 is a stable, resolvable local identifier — not a registered DOI. See Terms of use's "Citation policy" for the full explanation.